(Press-News.org) WHAT:
A dose-sparing intradermal mpox vaccination regimen was safe and generated an antibody response equivalent to that induced by the standard regimen at six weeks (two weeks after the second dose), according to findings presented today at the European Society of Clinical Microbiology and Infectious Diseases Global Congress in Barcelona. The results suggest that antibody responses contributed to the effectiveness of dose-sparing mpox vaccine regimens used during the 2022 U.S. outbreak.
The mpox virus has been present in west, central and east Africa for decades, with the first human case identified in 1970. In May 2022, a global mpox outbreak caused by the clade IIb strain of the virus provided the first epidemiologic evidence of community mpox transmission outside of historically affected countries. The Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN, sold as JYNNEOS) vaccine was made available to help contain the outbreak in the United States. The National Institutes of Health’s (NIH) National Institute of Allergy and Infectious Diseases (NIAID) sponsored a study of dose-sparing strategies to extend the limited vaccine supply.
The mid-stage study enrolled 225 adults aged 18 to 50 years in the United States who had not previously been vaccinated against mpox or smallpox. Participants were randomized to receive either the standard Food and Drug Administration-approved MVA-BN regimen, a regimen containing one-fifth of the standard dose, or one with one-tenth of the standard dose. The standard dose was injected under the skin (subcutaneously), while the dose-sparing regimens were injected between layers of the skin (intradermally). Participants in all study arms received two injections 28 days apart and were monitored for safety and immune response.
Two weeks after the second dose (study day 43), participants who received one-fifth of the standard dose had antibody levels equivalent to those of participants receiving the standard MVA-BN regimen, based on predefined criteria. By day 57, participants who received one-fifth of the standard dose had lower antibody levels than those in the standard regimen arm; the clinical significance of this difference is unknown. Participants who received one-tenth of the standard dose had inferior antibody levels at all measurements. The most reported adverse events were mild, local injection-site reactions. Adverse events were similar across all arms of the trial, and no serious adverse events related to the vaccine were reported.
The authors note that because there are no defined correlates of protection against mpox—immune processes confirmed to prevent disease—these findings cannot predict the efficacy of dose-sparing regimens with certainty. Real-world data from the Centers for Disease Control and Prevention and others have shown similar vaccine effectiveness for the dose-sparing regimen given intradermally and the standard regimen given subcutaneously. A study of the standard MVA-BN regimen in adolescents is ongoing and will report findings later this year.
NIH is grateful to the research sites and volunteers who participate in studies to improve the mpox response.
For more information about this study, please visit ClinicalTrials.gov and use the identifier NCT05512949.
REFERENCE:
Frey et al. Safety and Immunogenicity of Fractional Doses of Modified Vaccinia Ankara-Bavarian Nordic. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Barcelona, Spain. Saturday, April 27, 2024.
WHO:
Andrea Lerner, M.D., M.S., medical officer in NIAID’s Division of Microbiology and Infectious Diseases, is available to discuss this research.
CONTACT:
To schedule interviews, please contact NIAID News & Science Writing Branch, 301-402-1663, niaidnews@niaid.nih.gov.
NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit https://www.nih.gov/.
NIH...Turning Discovery Into Health®
END
Personalised “cocktails” of antibiotics, probiotics and prebiotics hold great promise in the treatment of a common form of irritable bowel syndrome (IBS), the ESCMID Global Congress (formerly ECCMID) in Barcelona, Spain (27-30 April) will hear.
Post-infection IBS (PI-IBS) is a form of irritable bowel syndrome that occurs after gastroenteritis or food poisoning.
Lead researcher Professor Maurizio Sanguinetti, of the Università Cattolica del Sacro Cuore, Rome, Italy, says: “Estimates vary, but research ...
Some immune-enhancing therapies already exist, and their use could be investigated while other immunomodulatory drugs specific to different sub-groups of TB disease are being developed
Experts are working on novel immune-enhancing therapies called host-directed therapies to use the body’s own immune system to target tuberculosis, with hopes that they could tackle even the drug-resistant forms of the disease. In a presentation at this year’s ESCMID Global Congress (formerly ECCMID) in Barcelona (27-30 April), Associate Professor Susanna Brighenti, Center for Infectious Medicine (CIM), ANA Futura at the Karolinska ...
Individuals requiring blood transfusion are a vulnerable population, often with debilitating conditions like cancer, and transfusion-transmitted malaria is often fatal.
Current serological tests used to identify “at risk” donors are not sensitive enough to completely eliminate malaria transfusion risk.
The current challenges are to optimise the testing strategy to minimise the loss of blood products (especially those rare blood phenotypes) and to enhance screening sensitivity for infectious immuno-tolerant donors who are difficult to identify.
**ECCMID has now changed its name to ESCMID Global, please credit ...
**ECCMID has now changed its name to ESCMID Global, please credit ESCMID Global Congress (formerly ECCMID, Barcelona, Spain, 27-30 April) in all future stories**
Antimicrobial resistance (AMR) is continuing to increase globally, with rates of AMR in most pathogens increasing and threatening a future in which every day medical procedures may no longer be possible and infections thought long dealt with could kill regularly again. As such, new tools to battle AMR are vitally needed.
In a new research review at this year’s ESCMID Global Congress (formerly ECCMID – Barcelona 27-30 April) shows ...
In the second new research review on this subject, Assistant Prof. Ibrahim Bitar, Department of Microbiology, Faculty of Medicine and University Hospital in Plzen, Charles University in Prague, Plzen, Czech Republic, will give an overview of the molecular biology of CRISPR technology in explaining how it can used to tackle antimicrobial resistance.
Clustered regularly interspaced short palindromic repeats (CRISPRs) and CRISPR associated genes (cas) are widespread in the genome of many bacteria and are a defence mechanism against foreign ...
For sports fans, places like Fenway Park, Wembley Stadium or Wimbledon's Centre Court are practically hallowed ground.
Archaeologists at the University of Cincinnati found evidence of similar reverence at ballcourts built by the ancient Maya in Mexico.
Using environmental DNA analysis, researchers were able to identify a collection of plants used in ceremonial rituals in the ancient Maya city of Yaxnohcah. The plants, known for their religious associations and medicinal properties, were discovered beneath a plaza floor upon which a ballcourt was built.
Researchers said the ancient Maya likely made a ceremonial offering ...
Scott Curran, group leader for Fuel Science and Engine Technologies Research at the Department of Energy’s Oak Ridge National Laboratory, has been named a Fellow of SAE International and the American Society of Mechanical Engineers, or ASME.
Curran is one of only 24 fellows selected from the more than 128,000 SAE members and one of only 3,336 fellows selected out of the 69,247 ASME members.
SAE recognized Curran for his distinguished contributions to transportation science, including advancing real-world advanced combustion strategies, alternative fuels utilization, and next-generation vehicle technologies for a more sustainable mobility future. ...
Researchers have found two novel types of attacks that target the conditional branch predictor found in high-end Intel processors, which could be exploited to compromise billions of processors currently in use.
The multi-university and industry research team led by computer scientists at University of California San Diego will present their work at the 2024 ACM ASPLOS Conference that begins tomorrow. The paper, "Pathfinder: High-Resolution Control-Flow Attacks Exploiting the Conditional Branch Predictor," is based on findings from scientists from UC San ...
The American Institute of Biological Sciences (AIBS) and the Southeastern Universities Research Association (SURA) are pleased to announce that Kristine Zikmanis has been selected for the 2024 Inclusive, Diverse, Equitable, Accepting, and Accessible (IDEA2) Public Policy Fellowship. This new professional development opportunity provides young scientists with valuable first-hand experience in science policy.
Kristine Zikmanis is a Ph.D. candidate in the Department of Biological Sciences at Florida International University. As an ecologist, Zikmanis studies animal behavior and has a strong interest in research at the intersection of ecology and ...
SCN2A related-disorders, although rare in the general population, are one of the more common single-gene neurodevelopmental conditions characterized by infantile seizures, autism spectrum disorder and intellectual disabilities
Severity of these disorders varies widely from person to person
Findings should help better identify patients who are most appropriate for clinical trials of new precision medicines and gene therapies
CHICAGO --- A genetic change or variant in a gene called SCN2A is a known cause of infantile seizures, autism spectrum disorder and intellectual disability, as well as a wide range of other moderate-to-profound impairments in mobility, ...
